Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

News

Trading Ideas

Elon Musk respalda Mounjaro en la batalla contra Ozempic. ¿Qué implican sus opiniones para la industria de pérdida de peso?

Medicamentos para adelgazar: La batalla entre Mounjaro y Ozempic con Elon Musk como protagonista

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

Biotech

Large Cap

Health Care

Movers

General

Novo Nordisk revela datos sobre Amycretina, un nuevo medicamento para pérdida de peso, que mostró una baja del 13,1% en peso en 12 semanas.

Novo Nordisk presenta resultados de su nuevo fármaco para pérdida de peso, Amycretina

Novo Nordisk AS

Precidian ETFs Trust Novo Nordisk A/S B Shares ADRhedged

Novo Resources Corp Warrants (27/08/2023)

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Tidal Trust II Defiance Daily Target 2X Long NVO ETF

Novo Nordisk Says New Phase III Trial Of Obesity Drug Candidate Cagrisema Launching On Feb. 10 Will Study Long-Term Efficacy Of Cagrisema, Part Of Redefine Series; Says It Has Not Yet Posted Details About New Cagrisema Trial To Test Weight Loss In Obesity Patients Planned After Late-Stage Trial Data In December

https://clinicaltrials.gov/study/NCT06780449?spons=Novo%20Nordisk%20A%2FS&amp;titles=cagrisema&amp;rank=6`

Novo Nordisk To Begin New Phase III Trial Of Obesity Drug Candidate Cagrisema

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">the Senate Finance Committee.</a>
While Kennedy&#8217;s tone in each back-and-forth varied, depending on the senator, it was evident that Kennedy&#8217;s role in the new administration would have a tremendous impact on both pharma and insurance stocks.
<h3 class="wp-block-heading">Drug Price Negotiation</h3>
During one exchange about the high cost of drugs with Senator Catherine Cortez Masto (D-NV), Kennedy said: "Senator, my understanding is that the White House issued an executive order, I believe today, supporting the drug negotiations under the I.R.A. President Trump was very aggressive during his first term about negotiating drug prices."
In reality, Trump has not signed an executive order on the topic since he was sworn into office. A Wednesday news <a href="https://www.cms.gov/newsroom/press-releases/cms-statement-lowering-cost-prescription-drugs" target="_blank" rel="noreferrer noopener">release</a> from the Centers for Medicare and Medicaid Services said that lowering the cost of prescription drugs for Americans &#8220;a top priority&#8221; for the Trump administration and that he would work to improve the transparency of the negotiation process.
Perhaps Kennedy was recalling Trump&#8217;s first term. In 2020, then-45th President Trump <a href="https://www.benzinga.com/general/biotech/20/09/17482940/trump-signs-executive-order-to-lower-us-drug-prices-after-negotiations-with-drugmakers-fail">signed an executive order</a> on U.S. Medicare drug prices intending to reduce costs. Industry leaders, including Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla, criticized the move. Pfizer was seeking regulatory approval to expand its late-stage vaccine trial at the time.
If Trump signs such an order, it would be a rare show of support from his camp for a Biden-era initiative. In addition to Pfizer, it would also impact major companies like Bristol Myers Squibb, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
Last month, the Biden administration <a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations">identified the next 15 drugs</a> as subject to negotiation. The list included Ozempic and Wegovy — two expensive drugs for diabetes and obesity owned by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
See Also: <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">RFK Jr. Is A &#8216;Predator&#8217; Unfit For Office, Caroline Kennedy Says </a>
<h3 class="wp-block-heading">Insurance Providers</h3>
According to the <a href="https://www.nytimes.com/live/2025/01/29/us/rfk-jr-health-senate-hearing">New York Times</a>, Kennedy wasn&#8217;t exactly familiar with Medicare and Medicaid, but expressed support for Medicare Advantage, where private insurers provide coverage for elderly Americans.
Kennedy also called out what he considered to be &#8220;rapacious behavior by insurance companies." He even suggested he would support some of the efforts undertaken during the Biden administration to crack down on abusive tactics like denying care and overcharging the government.
Traders would be wise to keep an eye on how insurance stocks — especially those tied to Medicaid and Medicare providers — react if Kennedy is sworn in. The major players in this space include: 
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer in the U.S.; Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>); Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid managed care organizations; Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>); CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>); Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>); and Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>).
What&#8217;s Next: Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
The title also puts him in charge of the Food and Drug Administration, the National Institutes of Health and the Centers for Disease Control and Prevention.
He will appear before the Senate Committee on Health, Education Labor and Pensions on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43216758/well-go-as-far-as-im-allowed-trumps-plan-with-immigrants-starts-with-1-million-deportations" target="_blank" rel="noreferrer noopener">‘We'll Go As Far As I'm Allowed': Trump's Plan With Immigrants Starts With 1 Million Deportations</a></li>
</ul>
Image: Shutterstock

Politics

Insurance

ABBV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders

The Food and Drug Administration on Tuesday approved Ozempic, the weight loss drug made by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), for the treatment of chronic kidney disease in patients who also <a href="https://www.benzinga.com/25/01/42875977/novo-nordisk-seeks-to-strengthen-its-obesity-pipeline-with-back-to-back-two-biobuck-deals">have type 2 diabetes. </a>
The Details: According to the Centers for Disease Control and Prevention, more than 35.5 million Americans have chronic kidney disease, often as a complication of type 2 diabetes. The new FDA approval allows for further expansion of Ozempic's use and potential coverage by health insurance plans.&nbsp;
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43254018/sofi-stock-falls-on-soft-guidance-despite-strong-quarter-with-record-member-growth-loan-originations-analyst"> SoFi Stock Falls On Soft Guidance Despite &#8216;Strong Quarter&#8217; With Record Member Growth, Loan Originations: Analyst&nbsp;</a>
The FDA approval "allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious consequences if left untreated," Anna Windle, a senior vice president at Novo Nordisk, said in a statement Tuesday, per a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-28/novo-s-ozempic-notches-approval-for-kidney-disease-widening-use?sref=TBDibEcD">report</a>.&nbsp;
Ozempic and other diabetes drugs known as GLP-1s have become popular and also well-known for their high cost.&nbsp;
Earlier in January, Novo Nordisk's diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy were all added to the U.S. Department of Health and Human Services list of drugs covered under Medicare Part D that<a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations"> have been selected</a> for mandated price negotiations in order to reduce <a href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets">prescription drug costs</a>.
The negotiations will take place in 2025, with the new prices slated to take effect in 2027.
NVO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Novo Nordisk shares ended Tuesday's session down 2.65% at $85.19.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43287988/microsoft-q2-preview">Microsoft Q2 Earnings Preview: Street &#8216;Too Optimistic&#8217; On Near-Term AI Returns?&nbsp;</a></li>
</ul>
Photo: Shutterstock

Ozempic Receives FDA Approval To Treat Kidney Disease

<ul>
<li>Ozempic&#xAE; is now indicated to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease</li>
<li>The approval is based on the results of the pivotal FLOW phase 3b kidney outcomes trial and addresses a critical need for adults with type 2 diabetes living with this common comorbidity of chronic kidney disease&nbsp;</li>
</ul>
PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic&#xAE;&nbsp;to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD).1&nbsp;This approval, along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular events in adults also with known heart disease, establishes Ozempic&#xAE;&nbsp;(semaglutide) injection 0.5 mg, 1 mg, or 2 mg as the most broadly indicated glucagon-like peptide-1 receptor agonist (GLP-1 RA) in its class.

FDA Approves Ozempic As The Only GLP-1 RA To Reduce The Risk Of Worsening Kidney Disease And Cardiovascular Death In Adults With Type 2 Diabetes And Chronic Kidney Disease

The rise of appetite-suppressing drugs like Ozempic is changing the way Americans eat, but there's a twist: <a href="https://www.benzinga.com/cannabis">cannabis</a> legalization is pulling consumer behavior in the opposite direction. Bloomberg's <a href="https://www.bloomberg.com/prognosis?sref=TBDibEcD">Prognosis newsletter</a> recently dug into this fascinating interplay, highlighting how these two trends are reshaping the food industry and public health.
<h3 class="wp-block-heading">The Ozempic Effect: Appetite On Pause</h3>
Ozempic, Wegovy and other GLP-1 agonists have become household names for their remarkable ability to help people shed pounds. These drugs don't just curb appetite, they're also influencing what people buy. According to a <a href="https://www.bloomberg.com/news/articles/2024-02-16/ozempic-users-cut-grocery-spending-by-up-to-9-survey-finds">Morgan Stanley report</a>, households using GLP-1 drugs have cut their spending on snacks, pastries and ice cream by 6% to 9%. Meanwhile, healthier options like yogurt and vegetable snacks are seeing a boost, as companies like Danone (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DANOY#OTC">DANOY</a>) and Nestlé adjust their product lines to meet demand.
Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), maker of Ozempic, has even <a href="https://finance.yahoo.com/news/novo-nordisk-ceo-says-fielding-114820887.html">received calls</a> from food industry leaders worried about the drug's impact. And they have reason to be concerned: Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) has <a href="https://www.bloomberg.com/news/articles/2023-10-04/walmart-says-ozempic-weight-loss-drugs-causing-slight-pullback-by-shoppers">reported</a> that households with GLP-1 users are buying less food overall. As the popularity of these drugs grows, with the market <a href="https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs">projected</a> to hit $100 billion by 2030, the ripple effects are only just beginning.
<h3 class="wp-block-heading">Cannabis Legalization: The Munchies Are Big Business</h3>
On the flip side, marijuana legalization is sparking a very different trend. With recreational cannabis now legal in 24 states, the infamous &#8220;<a href="https://elplanteo.com/munchies/">munchies</a>&#8221; are giving a major boost to junk food sales. Researchers from the <a href="https://www.nber.org/papers/w33176">National Bureau of Economic Research</a> found that grocery spending on snacks, cookies and candy jumped nearly 9% in states that legalized recreational marijuana.
<h3 class="wp-block-heading">A Collision Of Cultural Forces</h3>
These two trends &#8211; Ozempic's appetite-suppressing revolution and cannabis' munchies-driven consumption &#8211; paint a complex picture of American eating habits. On one side, GLP-1 drugs are helping people slim down and rethink their diets. On the other, marijuana legalization is encouraging indulgence, particularly in the form of high-calorie comfort foods.
Companies are scrambling to adapt. Nestlé and Conagra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>), for instance, are launching new products designed to appeal to both GLP-1 users and cannabis consumers. Think high-protein, portion-controlled frozen meals that cater to health-conscious shoppers, alongside indulgent snacks that satisfy the munchies. It's a balancing act and a testament to the food industry's ability to pivot with the times.
<h3 class="wp-block-heading">The Bigger Picture: Health And Economics</h3>
Cannabis legalization has brought tangible economic benefits, including increased GDP, job creation and tax revenue for states where it's legal. For example, Colorado and California have reported billions in tax revenue since legalization. Moreover, cannabis policies have helped reduce arrests and shifted law enforcement resources toward other priorities, fostering a growing legal industry that has supported local economies.
At the same time, public health challenges remain. Research indicates mixed outcomes. While substance use and dependency have increased slightly in some states, other studies highlight a decrease in opioid-related deaths and alcohol consumption, suggesting cannabis can serve as a harm-reduction tool.
Meanwhile, GLP-1 drugs present their own set of challenges. While they offer a promising tool in combating obesity, their rapid adoption is forcing industries reliant on indulgent eating, from fast food to snacks, to rethink their strategies. Questions about the long-term effects of these drugs and their impact on consumer behavior remain unanswered.
<h3 class="wp-block-heading">What's Next?</h3>
The intersection of Ozempic's appetite suppression and cannabis's munchies effect highlights the complexity of consumer trends in the U.S. Will GLP-1 drugs lead to healthier lifestyles, or will the munchies win out? For now, it's clear that both trends are reshaping industries and pushing companies to innovate like never before.
Cover image made with Canva

Cannabis

DANOY

How Ozempic And Legal Weed Are Changing What America Eats

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Novo Nordisk.
This isn't normal.
The overall sentiment of these big-money traders is split between 43% bullish and 25%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $210,131, and 10 are calls, for a total amount of $550,131.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $120.0 for Novo Nordisk, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale activity within a strike price range from $55.0 to $120.0 in the last 30 days. 
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738000838_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$9.85</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$90.00</td>
<td>$96.9K</td>
<td>1.2K</td>
<td align="right">22</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$20.05</td>
<td>$19.2</td>
<td>$19.6</td>
<td>$90.00</td>
<td>$84.2K</td>
<td>262</td>
<td align="right">54</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$34.85</td>
<td>$34.8</td>
<td>$34.8</td>
<td>$55.00</td>
<td>$69.6K</td>
<td>46</td>
<td align="right">20</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$12.45</td>
<td>$12.15</td>
<td>$12.2</td>
<td>$75.00</td>
<td>$61.0K</td>
<td>240</td>
<td align="right">50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.4</td>
<td>$5.35</td>
<td>$5.4</td>
<td>$90.00</td>
<td>$54.0K</td>
<td>2.2K</td>
<td align="right">272</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>With a trading volume of 6,319,073, the price of NVO is up by 0.13%, reaching $88.08.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 9 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Market Whales and Their Recent Bets on NVO Options

Veru Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) stock is plummeting on Monday after the company released topline results from the Phase 2b QUALITY clinical study of enobosarm for weight reduction.
The study evaluates the safety and efficacy of enobosarm 3mg and enobosarm 6mg, compared to placebo in 168 older patients, greater than 60 years of age, who are overweight or have obesity and who are receiving Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy (semaglutide).
The primary endpoint was the change in total lean body mass, and key secondary endpoints were the change from baseline to 16 weeks in total fat mass, total body weight, and physical function as measured <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43223310/veru-announces-positive-topline-data-from-phase-2b-quality-clinical-study-enobosarm-preserved-lean" rel="noreferrer noopener">by a stair climb test</a>.
The study met its primary endpoint with a statistically significant benefit in preservation of total lean body mass in all patients receiving enobosarm + semaglutide versus placebo + semaglutide at 16 weeks.
Secondary endpoints showed:
<ul>
<li>On average, patients on Enobosarm + semaglutide treatment lost 71% less lean mass than patients receiving Wegovy alone.</li>
<li>Patients on Enobosarm + semaglutide treatment on average lost 27% more fat mass than patients receiving Wegovy alone.</li>
<li>There appear to be minor differences in total body weight changes between the enobosarm+semaglutide group and placebo+semaglutide group at 16 weeks. Therefore, enobosarm+semaglutide improved changes in body composition and resulted in more selective and greater fat mass loss than in subjects receiving placebo + semaglutide.</li>
<li>The proportion of subjects who lost ≥10% stair climb power was statistically significant and clinically meaningfully reduced in the enobosarm + semaglutide groups compared to the placebo + semaglutide group.</li>
<li>Therefore, enobosarm reduced the proportion of patients who lost clinically significant physical function compared to subjects receiving semaglutide alone.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/news/asset-sales/24/12/42744301/veru-sells-fc2-condom-business-for-18-million-focuses-on-biopharma-pipeline" rel="noreferrer noopener">Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline</a>
Safety data remains blinded in the ongoing clinical study and the unblinded safety set will be available when the Phase 2b extension study is done in April 2025.
The Phase 2b extension trial is ongoing in which all patients stop receiving a GLP-1 RA but continue taking a placebo, enobosarm 3mg or enobosarm 6mg, for an additional 12 weeks.
The Phase 2b extension study will evaluate the maintenance of weight loss, meaning whether enobosarm can maintain muscle and prevent the fat and weight gain that occurs after discontinuing a GLP-1 RA.
Price Action: Veru stock is down 48.5% at 62 cents last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/01/43232734/nokia-scores-trio-of-global-deals-enhancing-network-security-and-high-capacity-routing" target="_blank" rel="noreferrer noopener">Nokia Scores Trio Of Global Deals, Enhancing Network Security And High-Capacity Routing</a></li>
</ul>
Image: Shutterstock

VERU

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Wall Street paused for a breather on Friday, with the S&amp;P 500 index hovering around the flatline at midday trading in New York after a five-day rally that pushed the market to fresh record highs this week. Meanwhile, investor attention shifted to <a href="https://www.benzinga.com/markets/forex">forex and gold markets.</a>
The greenback is experiencing its worst weekly performance since July 2023, as President Donald Trump refrained from imposing new tariffs during his first week and escalated pressure on the Federal Reserve, urging the central bank to lower interest rates. The U.S. dollar index – tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – dropped 0.7% on Friday, extending its weekly decline to 1.7%.
Adding to the dollar's downward momentum, the Bank of Japan raised interest rates by 25 basis points to 0.5%, the highest level since 2008, in a move that broadly met expectations.
Gold capitalized on the dollar's weakness and rising tensions between the president and the central bank, marking another week of strong gains and approaching all-time highs. The bullion, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), was trading at $2,777 per ounce.
On the macro front, S&amp;P Global reported a slowdown in private sector growth in January, as the services sector faced an unexpected setback, despite manufacturing expanding for the first<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43195427/us-services-growth-slows-manufacturing-finally-expands-in-january-inflation-was-broad-based-expert-warns"> time in seven months.</a>
A warning came from the University of Michigan's consumer survey, which downwardly revised the January consumer confidence indicator and pointed to increasing trends of households making purchases in advance to avoid potential price hikes <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43197024/consumer-confidence-declines-as-buying-in-advance-trends-grow">linked to tariffs.</a>
In the cryptocurrency market, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) climbed 2.5% following Trump's executive order signed on Thursday, aimed at strengthening U.S. leadership in digital assets. 
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,314.96</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,119.65</td>
<td>0.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,541.76</td>
<td>-0.1 %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,861.02</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012425&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) eased 0.1% to $608.89.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.1% lower to $444.96.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) slipped 0.4% to $530.73.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) stalled at $229.40.</li>
<li>The&nbsp;Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 0.9%; the&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.4%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul>
<li>American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) fell 2.4% after reporting fourth-quarter results. </li>
<li>Other stocks moving on quarterly results were Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), up 1.3%, NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>), up 4%, HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), down 3.2%, First Citizens BancShares Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>), up 3.1%, Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>), down 14.3%, Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), down 3.6%, Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), down 7.1%, and CSX Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>), down 2.8%. </li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) soared 8.1% after new weight loss drug amycretin showed strong trial results. </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43198272/us-stocks-hit-dot-com-era-valuations-vs-bonds-why-some-experts-remain-bullish">US Stocks Hit Dot-Com Era Valuations Vs. Bonds: Why Some Experts Remain Bullish</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Forex

Econ #s

Economics

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ERIC

FCNCA

ISRG

PowerShares DB US Dollar Index Bullish Fund

Stocks Stall, Gold Nears Record Highs As Dollar Faces Worst Week Since July 2023: What's Driving Markets Friday?

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Friday.
Shares of Customers Bancorp, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBI#NYSE">CUBI</a>) rose sharply during Friday's session following <a href="https://www.benzinga.com/quote/CUBI/earnings">upbeat quarterly earnings</a>.
Customers Bancorp posted quarterly core earnings of $1.36 per share, beating market estimates of $1.21 per share.
Customers Bancorp shares jumped 12.4% to $56.58 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) shares surged 22.6% to $139.01 after the company issued fourth-quarter earnings guidance above estimates and a year-over-year revenue increase. Multiple analysts raised their price targets on the stock.</li>
<li>Dana Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) surged 20% to $15.84 after the company provided FY25 guidance.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) shares jumped 19.1% to $3.62.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 15.7% to $11.04.</li>
<li>Himax Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMX#NASDAQ">HIMX</a>) gained 13.6% to $13.40.</li>
<li>Super Group (SGHC) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) rose 13.2% to $7.72 after Canaccord Genuity upgraded the stock from Hold to Buy and raised its price target from $5 to $10.</li>
<li>BlackSky Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NASDAQ">BKSY</a>) gained 13.1% to $13.50.</li>
<li>The Middleby Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIDD#NASDAQ">MIDD</a>) gained 12.5% to $163.85.</li>
<li>GDS Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NYSE">GDS</a>) jumped 10.1% to $23.37.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) gained 8.3% to $5.14.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) rose 7.6% to $87.22 after the company announced the completion of a Phase 1b/2a trial with subcutaneous Amycretin for people who are overweight or have obesity.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) gained 5.7% to $23.43.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it"> Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>

Intraday Update

BlackSky Technology Inc. Class A Common Stock

BKSY

CUBI

HIMX

LUNR

MIDD

SGHC

TWLO

Customers Bancorp, Twilio, Dana And Other Big Stocks Moving Higher On Friday

WIIM

Novo Nordisk shares are trading higher after the company announced the completion of a Phase 1b/2a trial with subcutaneous Amycretin for people who are overweight or have obesity.

On Friday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration.
The <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915251" rel="noreferrer noopener">trial</a> investigated the safety, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 people with overweight or obesity.
The trial was a combined single ascending, multiple ascending, and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations" rel="noreferrer noopener">Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations</a>
The primary endpoint was the treatment of emergent adverse events. When evaluating the effects of treatment if all people adhered to treatment&nbsp;from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks).
People treated with a placebo experienced an estimated 1.9%, 2.3%, and 2.0% body weight gain, respectively.
The safety profile of amycretin was consistent with incretin-based therapies.
The most common adverse events with amycretin were gastrointestinal, and the vast majority were mild to moderate in severity.
Based on the results, Novo Nordisk is planning further clinical development of amycretin in adults with overweight or obesity. Last week, Novo Nordisk released headline results from the STEP UP Phase 3b trial in the <a target="_blank" href="https://www.benzinga.com/25/01/43055832/novo-nordisks-higher-dose-of-wegovy-shows-weight-loss-of-around-21-phase-3-data-shows" rel="noreferrer noopener">global STEP program</a>.
When evaluating the effects of treatment if all people adhered to treatment&nbsp;from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo.
Price Action: NVO stock is up 10.80% at $89.90&nbsp;during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43186252/ericsson-q4-earnings-sales-climb-1-north-america-shines-dividend-raise-guidance-and-more" target="_blank" rel="noreferrer noopener">Ericsson Q4 Earnings: Sales Climb 1%, North America Shines, Dividend Raise, Guidance And More</a></li>
</ul>
Image via Shutterstock

Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

Novo Nordisk Successfully Completes Phase 1b/2a Trial With Subcutaneous Amycretin In People Overweight Or With Obesity

On Wednesday, IMMvention Therapeutix, Inc. announced a strategic collaboration and license agreement with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions.
The <a target="_blank" href="https://www.globenewswire.com/news-release/2025/01/22/3013435/0/en/IMMvention-Therapeutix-Enters-Strategic-Collaboration-with-Novo-Nordisk-to-Develop-Oral-Therapies-for-Sickle-Cell-Disease-and-Other-Chronic-Diseases.html" rel="noreferrer noopener">partnership</a> will leverage IMMvention's investigational small-molecule BACH1 inhibitors.
BACH1 is thought to be a key regulator of cellular responses, oxidative stress and inflammation in multiple disease states.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations" rel="noreferrer noopener">Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations</a>
In preclinical development, IMMvention's orally dosed BACH1 inhibitors can potentially increase fetal hemoglobin, which is believed to ameliorate SCD disease pathology.
Under the agreement, Novo Nordisk will gain an exclusive worldwide license to IMMvention's BACH1 program. The companies will work together closely to advance BACH1 inhibitors from the program to development candidate nomination.
Upon or before the nomination of a development candidate, Novo Nordisk will take over all further development, regulatory submissions and commercialization worldwide.
Separate from the systemic BACH1 inhibitors that are part of the collaboration, IMMvention has retained the rights to develop certain brain-penetrant BACH1 inhibitors.
Brain penetrant BACH1 inhibitors have the potential to address diseases such as Parkinson's, Alzheimer's, and other diseases where dysregulation of BACH1 is thought to contribute to disease pathology.
IMMvention's website&nbsp;<a target="_blank" href="https://www.immventionthera.com/approach-and-pipeline" rel="noreferrer noopener">lists</a> the anticipated milestones, with Investigational New Drug-IND enabling studies and Phase 1 clinical trials in 2026/27.
Price Action: NVO stock is down 0.27% at $80.82 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43127009/textron-reports-mixed-q4-faces-challenges-in-aviation-and-industrial-segments" target="_blank" rel="noreferrer noopener">Textron Reports Mixed Q4, Faces Challenges In Aviation And Industrial Segments</a></li>
</ul>

Contracts

Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 10 years by 1.92% on an annualized basis producing an average annual return of 13.38%. Currently, Novo Nordisk has a market capitalization of $354.66 billion. 
Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $3,537.42 today based on a price of $79.88 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737472514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) revealed 11 unusual trades.
Delving into the details, we found 72% of traders were bullish, while 18% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $712,181, and 5 were calls, valued at $327,380.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $100.0 for Novo Nordisk, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Novo Nordisk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Novo Nordisk's significant trades, within a strike price range of $70.0 to $100.0, over the past month.
<h3>Novo Nordisk Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737470739_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.4</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$70.00</td>
<td>$250.5K</td>
<td align="right">631</td>
<td>1.8K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$70.00</td>
<td>$209.3K</td>
<td align="right">631</td>
<td>907</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.25</td>
<td>$3.3</td>
<td>$70.00</td>
<td>$137.6K</td>
<td align="right">631</td>
<td>449</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.1</td>
<td>$9.7</td>
<td>$10.1</td>
<td>$80.00</td>
<td>$101.0K</td>
<td align="right">282</td>
<td>100</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$3.0</td>
<td>$2.86</td>
<td>$3.0</td>
<td>$77.00</td>
<td>$96.3K</td>
<td align="right">26</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 353,083, the NVO's price is up by 1.36%, now at $79.76. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 15 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Decoding Novo Nordisk's Options Activity: What's the Big Picture?

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) shares plummeted 35.42% after short seller firm Muddy Waters Research announced they <a href="https://www.benzinga.com//node/43040046" target="_blank" rel="noreferrer noopener">initiated a short position in the company</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock plunged 19.38% after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below <a href="https://www.benzinga.com//node/42946454" target="_blank" rel="noreferrer noopener">analyst estimates of $2.951 billion</a>. Morgan Stanley maintained an Equal-Weight rating and lowered the <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $70 to $38</a>.</li>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock declined 14.86%. In a recent X post, CNBC's Jim Cramer <a href="https://www.benzinga.com//node/43053808" target="_blank" rel="noreferrer noopener">steered investors toward</a> quantum stocks, suggesting they reinvest gains from GameStop into Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>).</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares dipped 12.91% following a report suggesting that Trump is considering an executive order to save TikTok from a U.S. ban.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares were down 10.81%. The company disclosed that its second Pioneer spacecraft for Varda Space Industries, Inc. is<a href="https://www.benzinga.com//node/43028933" target="_blank" rel="noreferrer noopener"> successfully operating in orbit</a>.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) stock lost 9.51% last week despite Guggenheim <a href="https://www.benzinga.com/quote/ntra/analyst-ratings" target="_blank" rel="noreferrer noopener">raising the price forecast</a> from $170 to $200. The company is due to provide a roadmap and outlook at the J.P. Morgan Healthcare Conference.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock decreased 9.27%  after the company issued FY24 revenue guidance <a href="https://www.benzinga.com//node/42976923" target="_blank" rel="noreferrer noopener">below the previous estimate</a>.</li>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) stock fell 9.22% after the company issued FY25 guidance with <a href="https://www.benzinga.com//node/42971328" target="_blank" rel="noreferrer noopener">its midpoint below estimates</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) shares declined 8.89% after Moderna issued 2025 revenue <a href="https://www.benzinga.com//node/42951363" target="_blank" rel="noreferrer noopener">guidance below analyst estimates</a>.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares fell 8.89% after Ozempic and Wegovy were included in a list of 15 medications for <a href="https://www.benzinga.com//node/43062779" target="_blank" rel="noreferrer noopener">Medicare drug price negotiations</a>.</li>
<li>BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) shares tumbled 8.68%. The company initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the <a href="https://www.benzinga.com//node/42953403" target="_blank" rel="noreferrer noopener">Unified Patent Court (UPC) in Munich, Germany</a>.</li>
</ol>
Photos courtesy: Shutterstock

Equities

Short Sellers

BMRN

BNTX

FTAI

ICLR

MRNA

NTRA

RGTI

RKLB

SNAP

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk.
Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 21 trades.
If we consider the specifics of each trade, it is accurate to state that 71% of the investors opened trades with bullish expectations and 28% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $201,386 and 16, calls, for a total amount of $1,105,756.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $52.5 to $120.0 for Novo Nordisk over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Novo Nordisk stands at 1078.84, with a total volume reaching 5,467.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk, situated within the strike price corridor from $52.5 to $120.0, throughout the last 30 days.
<h3>Novo Nordisk Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737139533_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.65</td>
<td>$2.55</td>
<td>$2.65</td>
<td>$90.00</td>
<td>$291.5K</td>
<td>1.8K</td>
<td>1.1K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.85</td>
<td>$17.8</td>
<td>$17.85</td>
<td>$70.00</td>
<td>$183.8K</td>
<td>224</td>
<td>106</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.91</td>
<td>$85.00</td>
<td>$97.7K</td>
<td>1.0K</td>
<td>172</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.9</td>
<td>$3.85</td>
<td>$3.85</td>
<td>$80.00</td>
<td>$80.4K</td>
<td>661</td>
<td>1.0K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$12.2</td>
<td>$12.05</td>
<td>$12.15</td>
<td>$70.00</td>
<td>$60.7K</td>
<td>47</td>
<td>56</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>With a trading volume of 13,377,152, the price of NVO is down by -5.35%, reaching $78.63.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 19 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Novo Nordisk Unusual Options Activity

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">prescription drug costs</a>.
These negotiations, mandated by the Inflation Reduction Act, will take place in 2025, with the new prices slated to take effect in 2027.
The selected drugs, used to treat conditions like cancer, diabetes, and asthma, represented approximately $41 billion in Medicare Part D costs between November 2023 and October 2024, accounting for 14% of the program's total expenses.
Under the finalized <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower" rel="noreferrer noopener">guidance</a> for the second negotiation cycle, drug manufacturers have until February 28, 2025, to decide on their participation.
The selected drug list for the second cycle of negotiations is:&nbsp;
<ul>
<li>Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy.</li>
<li>Pfizer Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Ibrance for breast cancer and Xtandi for prostate cancer.</li>
<li>GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Asthma and Chronic obstructive pulmonary disease treatment Trelegy Ellipta and Breo Ellipta.</li>
<li>Teva Pharmaceutical Industries Ltd.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Huntington's disease and Tardive dyskinesia drug Austedo, Austedo XR.</li>
<li>Abbvie Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) irritable bowel syndrome treatment Linzess and depression drug Vraylar.</li>
<li>Bristol-Myers Squibb Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Pomalyst for a type of blood cancer.</li>
<li>Boehringer Ingelheim's lung disease drug Ofev and diabetes med Tradjenta.</li>
<li>AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) cancer drug Calquence</li>
<li>Salix Pharmaceuticals' irritable bowel syndrome drug Xifaxan</li>
<li>Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) diabetes drug Janumet; Janumet XR.</li>
<li>Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) psoriasis drug Otezla</li>
</ul>
CMS will evaluate factors such as the drug's clinical benefit, its role in addressing unmet medical needs, and its impact on specific populations, alongside considerations for research, production, and distribution costs.
The first negotiation cycle in 2023 resulted in agreements for price reductions on 10 drugs, with discounts ranging from 38% to 79% off list prices.
The new prices, effective January 2026, are expected to save $6 billion in prescription drug costs annually and reduce out-of-pocket expenses for Medicare beneficiaries by an <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">estimated $1.5 billion</a>.
Looking ahead, CMS plans to expand the program, selecting up to 15 additional drugs for the third cycle and 20 more in subsequent cycles. The Inflation Reduction Act also introduces an out-of-pocket cap of $2,000 for Medicare Part D enrollees starting in 2025. Approximately 11 million beneficiaries are expected to benefit from the cap, saving a projected $7.2 billion annually.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43055401/schlumberger-posts-strong-q4-results-raises-dividend-and-buybacks-championx-deal-to-strengthen-future-growth" target="_blank" rel="noreferrer noopener">Schlumberger Q4: Earnings Beat, Dividend Boost, Offshore Boom And More</a></li>
</ul>
Image via Shutterstock

Government

Regulations

AMGN

TEVA

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

Novo Nordisk shares are trading lower after Ozempic and Wegovy were included in a list of 15 medications for Medicare drug price negotiations.

Franklin International Growth Fund Q4 2024 Commentary

TNF Pharmaceuticals (TNFA), announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha TNF...

TNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1s

Jaguar's Mytesi could be used to treat GI side effects of GLP-1 weight loss drugs

Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)

BGY: Strong Dollar Weighs On International Markets, But Don't Ignore Them

Eli Lilly Stock's Correction Brings Opportunity

HHS Secretary nominee RFK Jr. faces contentious Senate hearing

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

ClearBridge International Growth ADR Portfolios Q4 2024 Commentary

RFK Jr. hails GLP-1 weight loss meds as 'miracle drugs'

ACWX

AIQUF

AIQUY

ASAZF

ASAZY

ASML

ASMLF

ASND

ATAI

ATLCY

ATLKY

AZNCF

CMPS

CYBN

DRUG

GHRS

JAGX

LDNXF

LNSTY

LVMHF

LVMUY

MBFJF

MNMD

MUFG

NONOF

NPXYY

NVAX

RELX

RLXXF

RYDAF

SBGSF

SBGSY

SHEL

SHOP

SNEJF

SONY

SPOT

SRRK

TCEHY

TCTZF

TNFA

TSMWF

TYNPF

UCBJF

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

NVO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Legal

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

Investors in Novo Nordisk A/S Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights – NVO

ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO

Comments

Novo Nordisk

Noticias

Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL